From Weight Loss to Courtrooms: The Ozempic Lawsuit Story
- The Spencer Law Firm
- Oct 3
- 5 min read
Do I qualify for an Ozempic lawsuit?
If you took Ozempic, Wegovy, Rybelsus, or Mounjaro and were diagnosed with gastroparesis, ileus, gallbladder disease, sudden vision loss (NAION), or clot-related complications, and you have medical records linking the drug to the injury, you may qualify. Strict filing deadlines apply in Texas; consider getting a free evaluation now.
What’s the status of the Ozempic MDL?
As of mid-2025, cases are consolidated in MDL No. 3094 (E.D. Pa.). Plaintiffs continue adding new filings. Leadership and early rulings shape the criteria for injury-proof and warning adequacy. Houston plaintiffs may file locally but proceed through the MDL process. (Cite outbound sources on page.)
Ozempic Lawsuit Guide (2025): What Houston Patients Need to Know
Houston courts are seeing a flood of Ozempic claims. Learn which side effects matter most, and how The Spencer Law Firm is helping victims seek justice.
Thousands of lawsuits are being filed across the U.S.—and Houston courts are seeing a surge. Here’s what you need to know about the Ozempic litigation and how The Spencer Law Firm is helping victims.
Why Are People Filing Ozempic Lawsuits?
Ozempic (semaglutide) became a household name as a diabetes and weight-loss drug. Its rapid popularity, fueled by social media and celebrity use, made it one of the fastest-growing prescriptions in Texas.
But with its rise came alarming reports: patients complaining of chronic vomiting, stomach paralysis, gallbladder issues, blood clots, and sudden vision loss.
Lawsuits now claim that Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro) failed to properly warn patients of these risks, despite mounting evidence.
Key Side Effects Named in Lawsuits
According to recent studies and FDA warnings, Ozempic and related drugs may cause:
Gastroparesis (stomach paralysis) – nausea, vomiting, and food remaining undigested.
Ileus & intestinal obstruction – painful blockages requiring hospitalization.
Gallbladder disease & gallstones – often leading to emergency surgery.
NAION (vision loss) – optic nerve damage that may cause sudden, permanent blindness.
Blood clots & cardiovascular risks – increased risk of stroke and other complications.
A JAMA Internal Medicine study highlighted increased gallbladder disease among semaglutide users, and in 2023, the FDA required label changes to reflect serious gastrointestinal risks.
The Status of Ozempic Litigation
The litigation has grown rapidly:
Aug 2023 – First Ozempic lawsuits filed in U.S. courts.
Apr 2024 – Federal Judicial Panel created MDL No. 3094 in Pennsylvania, consolidating.
Mid-2025 – Nearly 1,900 lawsuits are pending in the MDL, with new cases added weekly.
Houston patients are actively part of these lawsuits, as Texas is one of the states seeing a higher concentration of claims.
Do You Qualify for an Ozempic Lawsuit?
You may be eligible if you:
Took Ozempic, Wegovy, Rybelsus, or Mounjaro.
Developed gastroparesis, ileus, gallbladder disease, vision loss, or blood clot complications.
Have medical documentation linking the condition to the drug.
Experienced financial or emotional damages (medical bills, lost income, disability).
Time is critical. Each state, including Texas, enforces a statute of limitations. Delays could cost you the right to compensation.
Potential Compensation
Victims may recover damages for:
Medical treatment and future care
Lost wages and reduced earning ability
Disability or permanent impairment (such as blindness)
Pain, suffering, and reduced quality of life
Wrongful death benefits for surviving families
Houston’s Legal Perspective: The Spencer Law Firm’s Role in Ozempic Litigation
The Spencer Law Firm is not just another plaintiff’s office—it is built on a foundation of specialized drug injury litigation experience, with proven success in mass torts and multidistrict litigation (MDL). We bring both local Houston strength and national strategy to Ozempic cases.
Proven Track Record in Drug Injury & MDL Cases
Our attorneys have litigated complex product liability and pharmaceutical matters for years. In the Ozempic MDL (MDL No. 3094), courts appointed eight plaintiffs’ lawyers from across the U.S. into leadership roles to steer this complex litigation, recognizing the need for seasoned counsel in handling mass tort dynamics. Reuters In addition, Judge Gene Pratter’s leadership-selection process has been highlighted by Reuters as a model for fairness—she ensured even non-slate applicants could be heard before formalizing lead counsel. Reuters+1
Science, Labels & Risk — We Stay Ahead of Medical Evidence
We ground each claim in scientific data, regulatory updates, and real-world case law. For example:
A meta-analysis of 76 randomized trials found that use of GLP-1 receptor agonists (the drug class Ozempic belongs to) raises the risk of gallbladder and biliary diseases—especially at higher doses or over longer durations—with relative risks ranging from 1.27 to 1.55 depending on the condition. JAMA Network
The FDA’s label for Ozempic (semaglutide) now includes warnings for ileus (intestinal motility disorder) under postmarketing experience, indicating the manufacturer had to add more serious gastrointestinal risks. motleyrice.com
The FDA also reviews reports in its Adverse Event Reporting System (FAERS) showing cases of acute cholecystitis linked to GLP-1 agents, including semaglutide. JAMA Network+1
This means that when we take your case, we don’t just file generic claims—we align your medical facts with evolving science and regulatory admissions.
Local + National Strategy
We combine Houston courtroom knowledge with national litigation optics. While your case may be filed in Texas, it will be part of MDL No. 3094, subject to federal rules and joint leadership decisions. Judge Marston now oversees this MDL following Judge Pratter’s death, and early rulings by Judge Marston have already shaped pivotal issues—from how gastroparesis must be diagnosed, to whether label warnings override claims. Reuters+1
Clients choose us because they get strategic choices: local presence, plus access to national motions, discovery, and strategic negotiation via MDL leadership channels.
FAQs: Ozempic Lawsuits
How long do I have to file?
Most states, including Texas, limit claims to 1–2 years from the date of injury diagnosis.
Do I have to pay up front?
No. Spencer Law works on a contingency basis. You pay nothing unless we recover compensation.
What if I took Wegovy, Rybelsus, or Mounjaro?
Yes—these drugs are also included in the litigation.
Will I need to appear in court?
Many cases settle out of court. If a trial is necessary, our attorneys are fully prepared to fight for you.
Final Word: Protecting Houston Patients
The wave of Ozempic lawsuits is growing daily, and victims are stepping forward to demand accountability. If you or a loved one suffered serious side effects after taking Ozempic, you don’t have to fight alone.
📞 Contact The Spencer Law Firm at (713) 961-7770 or request a free consultation online today.
References
[1] Reuters – Plaintiffs’ lawyers chosen to lead Ozempic litigation (Apr 2024)
[2] FDA Label Updates – Ozempic postmarketing reports include ileus; GI warnings strengthened
[3] JAMA Internal Medicine – GLP-1 receptor agonists and risk of gallbladder/biliary diseases (2022)
[4] Lawsuit Legal News – Nearly 1,900 cases pending in Ozempic MDL as of mid-2025
[5] State Legal Guides – Statute of limitations for product liability in Texas and other states
[6] Reuters – Ozempic litigation shifts to Judge Marston after Judge Pratter’s death (June 2024)
Disclaimer: This article is provided for informational and educational purposes only. It does not constitute legal, financial, medical, or professional advice. Laws and regulations change frequently, and the information may not reflect the most current developments. Reading this content does not create an attorney–client relationship.
While every effort is made to ensure accuracy and timeliness, the author and publisher make no warranties regarding the completeness or reliability of the information provided. The author and publisher disclaim any liability for actions taken or not taken based on this article.
Comments